Sarcoma Treatment Market Size, Trends And Forecast To 2033

The Sarcoma Drugs Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Sarcoma Drugs Market:

According to The Business Research Company’s Sarcoma Drugs Global Market Report 2024, The sarcoma drugs market size has grown strongly in recent years. It will grow from $1.28 billion in 2023 to $1.39 billion in 2024 at a compound annual growth rate (CAGR) of 8.7%. The  growth in the historic period can be attributed to healthcare infrastructure, treatment guidelines, patient advocacy groups, improved diagnosis methods, increased disease awareness.

The sarcoma drugs market size is expected to see strong growth in the next few years. It will grow to $1.97 billion in 2028 at a compound annual growth rate (CAGR) of 9.1%. The growth in the forecast period can be attributed to demand for novel therapies, healthcare investment, precision medicine, clinical trials and discoveries, research and development. Major trends in the forecast period include immunotherapy advancements, combination therapies, early diagnosis initiatives, biomarker research, patient-centric approach.

The rising cases of soft tissue sarcoma is expected to propel the sarcoma drugs market going forward. Soft tissue sarcoma is a cancer that start in the soft tissues of the body such as muscles, fat, tendons, lymph and nerves. Sarcoma drugs are used in the healthcare industry for the treatment of bone and soft tissue sarcoma by attacking cancer cells and dividing the cells. For instance, in January 2023, according to a report published by American Cancer Society, a US-based cancer fighting organization, in the US about 13,400 new soft tissue sarcomas will be diagnosed and around 5140 people are expected to die of soft tissue sarcomas in 2023.Therefore, the rising cases of soft tissue sarcoma is driving the growth of the sarcoma drugs market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

The sarcoma drugs market covered in this report is segmented –

1) By Treatment Type: Chemotherapy, Targeted Therapy
2) By Disease Indication: Malignant Bone Tumors, Soft Tissue Sarcomaz
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Development of new and innovative therapies have emerged as the key trend gaining popularity in the sarcoma drugs market. Major companies operating in the sarcoma drugs market are developing new and innovative therapy to strengthen their positing in the market. For instance, in November 2021, Aadi Bioscience, a US-based biopharmaceutical company, introduced Fyarro a new cancer med for the treatment for an ultrarare and aggressive form of sarcoma. Fyarro is a sirolimus protein bound particles that can be used as an injectable suspension in adults with advanced perivascular epithelioid cell tumor (PEComa). According to the chief operating office of Aadi Bioscience, Fyarro will become a standard care for patients with PEComa.

The sarcoma drugs market report table of contents includes:

1. Executive Summary
2. Market Characteristics
3. Market Trends And Strategies
4. Impact Of COVID-19
5. Market Size And Growth
6. Segmentation
7. Regional And Country Analysis
27. Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis

Major Players:

  • Amgen Inc.
  • Bayer AG
  • Eisai Co. Ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline PLC


Related Reports:

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]

Follow Us On:
Healthcare Blog:
Global Market Model: